Abstract
Purpose
The purpose of this research was to characterize the pharmacokinetic parameters and to evaluate the absolute bioavailability of the targeted compound: Z-(±)-2-(1-benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol (BMABO), a novel radio-sensitization agent, after oral delivery.
Methods
Sprague–Dawley rats received a single oral dose of 20 mg/kg and this was compared with intravenous administration of the compound (1 mg/kg). Blood samples were collected at different time points, and plasma BMABO concentrations were determined using a new sensitive and specific LC/MS analytical method, which utilized electrospray ionization.
Results
The bioavailability of orally administered BMABO was determined by comparing plasma concentrations after oral gavage delivery with intravenous delivery. Following delivery of the oral dose, the average C max was 1,710 ± 503 ng/ml, and the AUC-value was found to be 3,561 ± 670 ng min kg/ml mg. Relative to the intravenous dose (100% bioavailability), the bioavailability was 6.2% after oral administration.
Conclusion
As the current studies demonstrate the novel radio-sensitization agent BMABO may have potential therapeutic valuable in cancer treatment. Further evaluation of the efficacy and toxicity of BMABO will determine the feasibility of the oral route for future clinical studies.
This is a preview of subscription content, log in via an institution to check access.
References
Dewhirst MW, Sim DA (1986) Estimation of therapeutic gain in clinical trials involving hyperthermia and radiotherapy. Int J hyperthermia 2:165–178
Dewhirst MW, Vujaskovic Z, Jones E, Thrall D (2005) Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 21:779–790
Kampinga HH, Dikomey E (2001) Hyperthermic radio-sensitization: mode of action and clinical relevance. Int J Radiat Biol 77:399–408
Locke JE, Bradbury CM, Wei SJ, Shah S, Rene LM, Clemens RA, Roti Roti J, Roti Horikoshi N, Gius D (2002) Indomethacin lowers the threshold thermal exposure for hyperthermic radio-sensitization and heat-shock inhibition of ionizing radiation-induced activation of NF-( B. Int J Radiat Biol 78:493–502
Sekhar KR, Sonar VN, Muthusamy V, Sasi S, Laszlo A, Sawani J, Horikoshi N, Higashikubo R, Bristow RG, Borrelli MJ, Crooks PA, Lepock JR, Roti Roti JL, Freeman ML (2007) Novel chemical enhancers of heat shock increase thermal radiosensitization through a mitotic catastrophe pathway. Cancer Res 67:695–701
Sonar VN, Parkin S, Crooks PA (2003) 2-(1-Benzyl-1H-indol-3-ylmethylene)-1-azabicyclo[2.2.2]octan-3-one. Acta Crystallogr E: Struct Rep Online E59:o1478–o1480
Van der Zee J, Gonzalez GD, Vernon CC, et al (1998) Therapeutic gain by hyperthermia added to radiotherapy. In: Kogelnik HD, Sedlmayer F (eds) Progress in radio-oncology, VI. Monduzzi Editore, Bologna, pp 137–145
Yau TM, Kim SC (1980) Local anaesthetics as hypoxic radio-sensitizers, oxic radio-protectors and potentiators of hyperthermic killing in mammalian cells. Br J Radiol 53:687–692
Acknowledgment
This investigation was supported in part by NIH/NCI PO1 CA104457.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al-Ghananeem, A.M., Albayati, Z.F., Malkawi, A. et al. A pharmacokinetic study on Z-(±)-2-(1-benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol; a novel radio-sensitization agent. Cancer Chemother Pharmacol 60, 915–919 (2007). https://doi.org/10.1007/s00280-007-0425-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-007-0425-8